Consumer expectations regarding product safety and transparency are prompting a re-evaluation of industry practices, with a notable increase in demand for clean cannabis standards. This shift indicates that consumers are increasingly scrutinizing how cannabis products are cultivated and processed, moving beyond a singular focus on cannabinoid potency.
The evolving landscape suggests a need for the regulated cannabis market to prioritize transparency, consistency, and product integrity to meet these new consumer demands, as reported by Cannabis Industry Journal.
Evolving Consumer Expectations for Clean Cannabis
New consumer data from Royal Queen Seeds, conducted with The Harris Poll highlights a significant change in what consumers expect from cannabis products. The study indicates that nearly three in four cannabis consumers (72%) express concern about pesticides in their cannabis. This figure represents an increase from previous years, reflecting a broader trend where consumers are more informed and demand higher safety standards from all products, including cannabis.
This scrutiny extends to sourcing, ingredients, and production practices. The data suggests that the industry, despite its regulatory frameworks, is not exempt from consumer demands for cleanliness and transparency, challenging business models that have historically prioritized high THC percentages above other quality metrics.
The Gap Between Regulation and Trust
While the regulated market has often been positioned as a safer alternative to illicit sources due to testing and compliance measures, recent findings suggest a growing disparity between this promise and consumer perception. Only 39% of Americans aged 21 and over believe the cannabis industry is fully transparent about pesticide testing, according to data from a study conducted with The Harris Poll.
This indicates that regulatory compliance alone does not automatically translate into consumer trust. The fragmented regulatory landscape, where standards and enforcement can vary, contributes to consumer uncertainty. For trust to be established, the industry must ensure that its safety processes are not only robust but also clearly communicated and visible to consumers.
Redefining Quality Beyond Potency
The consumer data also reveals a redefinition of what constitutes product quality. A full two-thirds of consumers surveyed stated they would choose cannabis grown without pesticides, even if it had a lower THC percentage. This challenges the long-held industry assumption that potency is the primary purchasing driver.
Instead, safety, consistency, and reliability are gaining equal, if not greater, importance. Consumers are also approaching cannabis with a more nuanced perspective, with more than half reporting that their use is tied to both enjoyment and health or wellness benefits. This dual purpose elevates expectations for product integrity and suggests that industry conversations should broaden to include terpenes, genetics, and overall product quality, moving beyond a sole focus on THC content to meet evolving clean cannabis standards.
Industry Response to Consumer Control
A clear signal of this changing mindset is the increasing interest in home cultivation. The same survey found that sixty-five percent of consumers are more likely to consider growing cannabis at home due to recent media coverage. This trend is rooted in a desire for greater control over product quality and transparency, particularly when consumers feel uncertain about the broader market.
Home cultivation offers a level of transparency that the commercial market has yet to consistently deliver. For the industry, this signifies an opportunity to invest in systems that make quality and safety foundational, proactively addressing consumer concerns with transparency and visible accountability. Education will also be critical, especially as interest in cannabis for wellness purposes continues to grow, ensuring consumers can make informed decisions regardless of their purchasing channel.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
